Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020
08:01pm, Thursday, 30'th Apr 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today
Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors
12:30pm, Thursday, 30'th Apr 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today
Atreca (BCEL) Receives a Buy from Canaccord Genuity
10:32am, Thursday, 30'th Apr 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca (BCEL) yesterday and set a price target of $23.00. The company's shares closed
Atreca (BCEL) Receives a Buy from Canaccord Genuity
10:31am, Thursday, 30'th Apr 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca (BCEL – Research Report) yesterday and set a price
Allogene Therapeutics (ALLO) Gets a Buy Rating from Canaccord Genuity
10:31am, Thursday, 30'th Apr 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO), with a price target of $36.00.
Allogene Therapeutics (ALLO) Gets a Buy Rating from Canaccord Genuity
10:31am, Thursday, 30'th Apr 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO – Research
Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD)
02:02pm, Wednesday, 29'th Apr 2020
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Gilead Sciences (GILD), with a price target of $81.00. The
Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD)
02:02pm, Wednesday, 29'th Apr 2020
In a report released today,
Salim Syed
from Mizuho Securities maintained a
Buy
rating on Gilead Sciences (
GILD
–
Research Report
), with a price target of
$81.00
. The company’s shares closed las
Canaccord Genuity Remains a Buy on Aptose Biosciences (APTO)
10:08am, Tuesday, 28'th Apr 2020
Canaccord Genuity analyst John Newman maintained a Buy rating on Aptose Biosciences (APTO) yesterday and set a price target of $13.00. The company's
Canaccord Genuity Believes Regeneron (REGN) Still Has Room to Grow
10:08am, Tuesday, 28'th Apr 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Regeneron (REGN), with a price target of $575.00. The
Contrasting Atara Biotherapeutics (NASDAQ:ATRA) & Acorda Therapeutics (NASDAQ:ACOR)
06:58am, Tuesday, 28'th Apr 2020
Atara Biotherapeutics (NASDAQ:ATRA) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the streng
7 Disruptive Biotech Stocks to Buy for 2025
02:56pm, Monday, 27'th Apr 2020
RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.
2 Top Biotech Stocks Under $10
11:56am, Monday, 27'th Apr 2020
Amarin and Atara Biotherapeutics could both be diamonds in the rough.
William Blair Remains a Buy on Aileron Therapeutics (ALRN)
04:06pm, Friday, 24'th Apr 2020
William Blair analyst Matt Phipps maintained a Buy rating on Aileron Therapeutics (ALRN) on April 22. The company's shares closed last Friday at $0.53.
William Blair Remains a Buy on Aileron Therapeutics (ALRN)
04:06pm, Friday, 24'th Apr 2020
William Blair analyst
Matt Phipps
maintained a
Buy
rating on Aileron Therapeutics (
ALRN
–
Research Report
) on April 22. The company’s shares closed last Friday at $0.53.
According to
TipRanks.co
